ProMIS Neurosciences reported interim Phase 1b data showing PMN310, which targets toxic amyloid oligomers rather than large plaques, produced no cases of amyloid-related imaging abnormalities (ARIA-E) in a cohort with high APOE4 representation. This selective approach may expand treatment access for genetically high-risk populations previously limited by safety concerns with conventional anti-amyloid therapies.
Key Points
- PMN310 targets early toxic oligomers, not accumulated plaques
- No ARIA-E cases reported in 61% APOE4 carrier population
- Early biomarker improvements suggest disease process interruption
Longevity Analysis
The distinction between targeting soluble oligomers versus insoluble plaques represents a fundamental shift in how the brain's protein misfolding cascade is understood and addressed. By intervening earlier in the pathological sequence—before toxic fragments accumulate into larger structures—this approach may prevent the neuroinflammatory cascade and vascular complications that both accelerate cognitive decline and trigger the imaging abnormalities that currently limit treatment access. For individuals carrying APOE4 variants, who face the highest Alzheimer's risk and most severe safety trade-offs, a therapy that avoids ARIA-related complications could transform whether disease modification becomes clinically achievable rather than contraindicated.
Original published by Longevity.Technology, by Kyle Umipig.